Key Highlights

  • BioAge Labs (NASDAQ:BIOA) dosed the first participant in QUELL-DME, a clinical study of oral BGE-102 for diabetic macular edema, with topline results expected in 2027 and findings intended to inform development for other NLRP3-linked retinal diseases.
  • The same NLRP3 inhibitor is also being tested in QUELL-CV, a parallel Phase 2 proof-of-concept cardiovascular trial in roughly 160 adults with obesity and elevated inflammatory markers, with topline data anticipated in the second half of 2026.
  • BioAge Labs (NASDAQ:BIOA) has reported being well capitalized following recent financings, including a 115 million dollar upsized public offering priced at USD 19.50 per share in January 2026, supporting research and clinical development across its NLRP3 and APJ programs.
  • Earlier Phase 1 data for BGE-102 showed rapid, profound reductions in a key inflammatory marker, hsCRP, alongside consistent decreases in IL-6 and fibrinogen, results that support the drug's potential across multiple organ systems and disease areas.

QUELL-DME Tests Oral BGE-102 for Diabetic Eye Disease

BioAge Labs (NASDAQ:BIOA), a clinical-stage biopharmaceutical company, announced dosing of the first participant in QUELL-DME, a controlled study evaluating oral BGE-102 in adults with diabetic macular edema. The trial assigns participants to different treatment approaches: one group receives anti-VEGF therapy with an oral placebo, another combines anti-VEGF treatment with BGE-102, and a third receives BGE-102 alongside a simulated injection, allowing the drug to be assessed both as a standalone treatment and in combination with existing standard-of-care therapy. The study's primary outcome is best-corrected visual acuity, with additional assessments examining retinal characteristics and biomarkers measured in the eye and in plasma. BioAge has said the QUELL-DME results are expected to inform its broader development strategy for other NLRP3-linked retinal diseases, including geographic atrophy, extending the drug's potential beyond diabetic eye disease alone.

A Parallel Cardiovascular Trial Adds a Nearer-Term Catalyst

The same BGE-102 compound is also being evaluated in QUELL-CV, a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept trial testing three once-daily oral doses in roughly 160 adults with obesity, elevated hsCRP and additional cardiovascular risk factors. That trial builds on earlier Phase 1 data showing rapid and profound reductions in hsCRP alongside consistent decreases in IL-6 and fibrinogen, inflammatory markers that support BGE-102's potential relevance across multiple organ systems rather than retinal disease alone. BioAge has guided for topline QUELL-CV data in the second half of 2026, positioning that readout as a nearer-term catalyst than the 2027 timeline for QUELL-DME results, giving investors two distinct binary events tied to the same underlying molecule across different indications.

Balance Sheet Strength Supports a Multi-Year Pipeline

BioAge Labs priced an upsized public offering of 5,897,435 shares at USD 19.50 per share in January 2026, raising approximately 115 million dollars in gross proceeds, with proceeds earmarked for research, clinical and Manufacturing activities across its NLRP3 and APJ programs. The company has described its Balance Sheet as well capitalized, with cash and marketable securities reported in prior quarters sufficient to fund operations well beyond the near-term QUELL-CV and QUELL-DME readouts, reducing near-term financing risk relative to many earlier-stage biotechs. BioAge is also developing long-acting injectable and oral small-molecule APJ agonists for obesity, giving the company a second pipeline pillar distinct from its NLRP3 inflammation programs, though the dual QUELL trials for BGE-102 remain the company's most immediate value-defining catalysts.

Where Things Stand

BioAge Labs has indeed dosed its first QUELL-DME participant, extending its NLRP3 inhibitor program into diabetic eye disease alongside the already-underway QUELL-CV cardiovascular trial for the same compound. The balance of evidence shows a well-funded, single-asset-concentrated biotech with two distinct binary catalysts on different timelines, a structure that offers multiple chances for validating data but also concentrates risk in one molecule's success. The next and nearer-term catalyst is topline QUELL-CV cardiovascular data expected in the second half of 2026, ahead of the longer-dated QUELL-DME readout in 2027.